Ixchel Pharma Information

Ixchel Pharma develops small-molecule drugs that ameliorate mitochondrial disease. We have devised a unique approach to identifying therapeutic drugs that hit mitochondrial targets with high specificity. Our approach generates safe therapeutics that target the molecular source of disease to cure the associated symptoms. Ixchel focuses on developing drugs that cure mitochondrial diseases for which there are currently no FDA-approved treatments. The majority of mitochondrial diseases are considered orphan and affect less than 200,000 people in the US. Ixchel has utilized a repurposing approach to isolate drugs for a number of debilitating orphan mitochondrial diseases including Friedreich's ataxia (FA), Mitochondrial Myopathy (MM), and Leber's hereditary optic neuropathy (LHON). In addition to developing treatments for orphan mitochondrial disease, Ixchel has developed drugs that target the underlying causes of type 2 diabetes and obesity, both of which are mitochondrial-influenced metabolic diseases. Ixchel has identified repurposed drugs as well as new chemical entities (NCEs) that target a known mitochondrial regulator of insulin signaling and mitochondrial fat oxidation.